GlassScriptPhysician profile
Tara Lee Morgan
NPI 1467190603
$3,409.84
in general payments reported to CMS, 2019-2025
27 companies · $1,674 in 2025
The $1,674 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $786 · 2024: $950 · 2025: $1,674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,409.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $893.60 | 2023-2025 | |
| Pfizer INC. | $548.09 | 2024-2025 | |
| Lilly USA, LLC | $244.50 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.21 | 2023-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $175.02 | 2023-2025 | Arexvy, Trelegy Ellipta, Bexsero |
| Axsome Therapeutics, INC. | $174.85 | 2025 | Sunosi, Auvelity |
| Sanofi-Aventis U.S. LLC | $146.51 | 2025 | |
| Corium, LLC | $145.54 | 2023-2025 | Azstarys |
| Xeris Pharmaceuticals, INC. | $123.83 | 2025 | Gvoke Hypopen |
| Sage Therapeutics, LLC | $99.62 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.65 | 2025 | |
| Astellas Pharma US INC | $76.01 | 2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $61.30 | 2024 | Quviviq |
| Novo Nordisk INC | $60.96 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $49.93 | 2023-2024 | Gardasil 9, M-M-R II, Proquad |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $44.06 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Seqirus USA INC | $43.16 | 2023-2025 | Flucelvax, Fluad, Fluad Quadrivalent |
| Dynavax Technologies Corporation | $35.64 | 2024-2025 | Heplisav-B |
| Amgen INC. | $32.60 | 2025 | Evenity, Otezla, Repatha |
| Dexcom, INC. | $25.74 | 2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $22.20 | 2025 | Zoryve |
| Sumitomo Pharma America, INC. | $17.11 | 2025 | Gemtesa |
| Mayne Pharma Commercial LLC | $17.07 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $16.96 | 2024 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.84 | 2023 | |
| Boston Scientific Corporation | $14.81 | 2024 | Watchman Access System |
| Exact Sciences Corporation | $14.03 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.